COR2ED - Oncology Medical Conversation Video
von COR2ED Medical Education
Metastatic TNBC cannot wait
Über diesen Podcast
Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy.
This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com
Folgen
Die neuesten 20 von 36 Folgen
- Metastatic TNBC cannot wait · 27 Min. · Staffel 6In this video podcast, Prof. Giuseppe Curigliano and Dr Javier Cortés explore how TROP2-directed antibody–drug conjugates (ADCs) are shaping 1st line treatment for metastatic…
- Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer · 23 Min. · Staffel 6Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer Key clinical takeaways: Metastatic breast cancer (mBC) is a complex, heterogeneous…
- Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification · 25 Min. · Staffel 5Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how…
- Understanding EP-NEC: Through Diagnosis, Treatment, and Support · 27 Min. · Staffel 5In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas…
- Exploring the role of targeted radiopharmaceutical treatment in NETs · 22 Min. · Staffel 5How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient…
- Tackling mPDAC: chemotherapy strategies that matter · 22 Min. · Staffel 5Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an…
- Understanding Rare NSCLC Mutations: Insights, access and support · 21 Min. · Staffel 5Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of…
- The HER2 diagnostic and treatment landscape in NSCLC · 19 Min. · Staffel 5Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC…
- The HER2 Diagnostic and Treatment Landscape in NSCLC · 21 Min. · Staffel 5Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives This is the first episode of a two-part series on the HER2 diagnostic and…
- ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses · 14 Min. · Staffel 5In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior…
- Best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer · 26 Min. · Staffel 5This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer. Dr Rena Callahan and Dr Roberto Salgado discuss key…
- Intermediate HCC – The evolving role of IO · 27 Min. · Staffel 5Intermediate HCC – The evolving role of IO In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul…
- Intermediate HCC – treatment options and strategies · 20 Min. · Staffel 5In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr…
- HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch · 26 Min. · Staffel 4Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast…
- Testing to treatment of BRAF-mutant metastatic NSCLC · 23 Min. · Staffel 4Testing to treatment of BRAF-mutant metastatic NSCLC In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF…
- HCC podcast series part 1: The use of IO in unresectable HCC · 23 Min. · Staffel 4In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC…
- BRAF-mutated CRC: testing to treatment · 26 Min. · Staffel 4Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments…
- Neuroendocrine tumours (NETs) – Shared decision-making. Part 2: Individualising treatment decisions · 23 Min. · Staffel 5In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared…
- Neuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journey · 30 Min. · Staffel 5In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the…
- Regional differences in NET: Treatment and future developments · 21 Min. · Staffel 4In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future…








